Sponsored Links

 

Displaying bosentan PowerPoint Presentations



Bosentan in Pulmonary Arterial Hypertension PPT

Presentation Summary : for Pulmonary Arterial Hypertension Isaac Kobrin, MD Head of Clinical Development Actelion Pharmaceuticals 9001.01 Advisors Bosentan Therapy for PAH Endothelin-1 (ET ...

Source : http://www.fda.gov/ohrms/dockets/ac/01/slides/3775s2_01_actelion.ppt

Pulmonary Hypertension - Welcome! — Pediatrics - UNC School ... PPT

Presentation Summary : Title: Pulmonary Hypertension Author: Children's Hospital of Philadelphia Last modified by: Windows User Created Date: 8/28/2007 5:20:13 PM Document presentation format

Source : http://pediatrics.med.unc.edu/education/current-residents/rotation-information/pediatric-intensive-care-unit/PHTN_Resident_Lecture.ppt

BENEFIT: Study design - CardioSource - Home PPT

Presentation Summary : Bosentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) and post-pulmonary endarterectomy pulmonary hypertension A pre-defined subgroup analysis ...

Source : http://www.cardiosource.com/img/Lang_benefit.ppt

Pulmonary Arterial Hypertension Associated with a ... PPT

Presentation Summary : Pulmonary Arterial Hypertension Associated with a Neuroendocrine Pancreatic Tumor Successfully Treated with Bosentan and Fluoxetine By Paul Strachan MD*, Subani ...

Source : http://lungtherapeutics.com/appDocs/Pulmonary_Arterial_Hypertension.ppt

SSPAH Template PPT

Presentation Summary : Bosentan is provided twice daily at a maintenance dose of 125 mg bid. Ambrisentan is a once-daily medication with two dosage levels, 5 mg or 10 mg. Bosentan is a ...

Source : http://www.medipixproductions.net/files/simplyspeaking2010/decks/pah/05_waxman.ppt

Pulmonary Hypertension for the Internist - Welcome to the UNC ... PPT

Presentation Summary : Monthly transaminase monitoring required for both Annual cost about $40,000 Bosentan (Tracleer) • 215 patients 70% IPAH 92% Class III • Week 16: 36 ...

Source : http://medicine.med.unc.edu/education/internal-medicine-residency-program/files/ppt/11.9.09%20Ford%20Pulmonary%20Hypertension%20for%20the%20Internist.ppt

Presentación de PowerPoint - EL COMPRIMIDO PPT

Presentation Summary : Bosentan can be efficacious in treating severe active digital ulcers in patients with systemic scleroderma. Bosentan appears to act rapidly, ...

Source : http://www.elcomprimido.com/INFORMED/PDC_HUSD18_AUTOINMUNES/PDC_HUSD18_Dr_Pallares_EndotelinaBiologicosEAS_parte1.ppt

Pulmonary Hypertension: The Other High Blood Pressure PPT

Presentation Summary : Pulmonary Hypertension: The Other High Blood Pressure ... Twice-daily bosentan (Tracleer) was the first of 4 currently approved oral therapies; ...

Source : http://lchpediatrics.weebly.com/uploads/1/1/5/4/11548021/pulmonary_hypertension.ppt

Tezo2_Temp.ppt - Food and Drug Administration PPT

Presentation Summary : Title: Tezo2_Temp.ppt Subject: Tezosentan and Bosentan Author: Chris and Marty Last modified by: FDA.CDER Created Date: 6/29/1998 5:56:19 PM Document presentation format

Source : http://www.fda.gov/ohrms/dockets/ac/01/slides/3775s2_02_Actelion%20backups.ppt

Chronic Thromboembolic Pulmonary Hypertension PPT

Presentation Summary : Bosentan – endothelin receptor antagonist. Balloon angioplasty. Has been done successfully. ... Chronic thromboembolic disease is uncommon, but not rare.

Source : http://medicine.med.unc.edu/education/internal-medicine-residency-program/files/ppt/6.30.09%20Galpin%20Chronic%20Thromboembolic%20Dz.pptx

Idiopathic Pulmonary Fibrosis Standards of Care ... PPT

Presentation Summary : Idiopathic Pulmonary Fibrosis Standards of Care & Investigational Therapies Stephen K. Frankel, MD, FCCP ... 2+ years Enrollment status Bosentan (Tracleer): ...

Source : http://www.coalitionforpf.org/wp-content/uploads/2013/02/FrankelLivingwithIPF.ppt

PowerPoint Presentation PPT

Presentation Summary : Although relatively little evidence supports combined use of bosentan and epoprostenol, bosentan treatment was continued during the initiation of epoprostenol therapy.

Source : http://phdres.caregate.net/curriculum/ppt_files/PAH%20talk%202006/zxs.ppt

Slide 1 PPT

Presentation Summary : Bosentan: ~35-40k per year Sildenafil: ~12-15k per year Inhaled Iloprost: ~60k per year IV Prostacyclins: ~60-120k per year Pulmonary Arterial Hypertension ...

Source : http://sciotocountymedicalsociety.org/documents/Franco-PortmanGrandRoundsSept2008.ppt

PAH PPT

Presentation Summary : ... Medications Prostanoids – epoprostenol, treprostinil, and iloprost ERA’s (endothelin receptor antagonists) – bosentan and ambrisentan Phosphodiesterase-5 ...

Source : http://bmhgt.com/wp-content/uploads/2009/01/pulmonary-hypertension.ppt

Pulmonary Complications of Sickle Cell Disease PPT

Presentation Summary : Pulmonary Complications of Sickle Cell ... ASSET-1 and 2: Bosentan in PH of SCD Randomized placebo controlled trials of bosentan in PAH or PVH of SCD Industry ...

Source : http://www.bumc.bu.edu/im-residency/files/2014/04/Pulmonary-Complications-of-Sickle-Cell-Disease-Klings-2.3.14.ppt

Updates in Pulmonary Hypertension - Home of Team RT PPT

Presentation Summary : In pulmonary hypertension, also, ... continuous infusion Tracleer® (bosentan) Remodulin® (treprostinil) – SQ and IV Ventavis® (iloprost) Revatio® ...

Source : http://teamrt.net/pages/pah/pah_presentation2.ppt

Pulmonary Arterial Hypertension PPT

Presentation Summary : Pulmonary Embolism Part of VTE Potentially fatal Can complicate hospital admission Preventable Tests poor Risk factors Surgery ... Bosentan, sitaxentan PDE4 ...

Source : http://www.mededcoventry.com/Specialties/Respiratory/Week%203%20-%20PE%20PAH%20and%20sleep.ppt

Update on Clinical Trials - Coalition for Pulmonary Fibrosis PPT

Presentation Summary : Division of Pulmonary, Critical Care, ... Bosentan: a novel agent for the treatment of pulmonary hypertension. Int J Clin Pract. 2004;58:69-73. Walter N, ...

Source : http://www.coalitionforpf.org/wp-content/uploads/2013/03/ClinicalTrialsSahn.ppt

Pre-clinical data: An update - Krause und Pachernegg - Verlag ... PPT

Presentation Summary : Addition of bosentan to macitentan did not lead to further reductions in MAP Macitentan then vehicle Macitentan then bosentan -50 -40 -30 -20 -10 0 Animal model p ...

Source : http://www.kup.at/kup/bildsatz/308.ppt

Scleroderma Dermatomyositis - University of Colorado Denver PPT

Presentation Summary : Bosentan. Epoprostenol. PDE5 inhibition. DMARDS. methotrexate. MMF (CellCept/Myfortic) Cyclophosphamide. Steroids, LD(<15mg) N-acetylcysteine. Rituximab. Stem cell ...

Source : http://www.ucdenver.edu/academics/colleges/medicalschool/departments/medicine/GIM/education/ContinuingEducation/Documents/SSc%20101%20rev%20june%202013.pptx

Cardiac Glycosides and Therapy of Congestive Heart Failure PPT

Presentation Summary : Cardiac Glycosides and Therapy of Congestive Heart Failure ... Natriuretic peptide Bosentan (Tracleer®) Endothelin receptor antagonist Epoprostenol ...

Source : http://iris.nyit.edu/still/Cardiology/2003_04/17_Cardiac_Glycosides_Therapy_Congestive_Heart_Failure.ppt

Chapter 16 Cholinesterase Inhibitors - El Paso Community College PPT

Presentation Summary : ... Iloprost (Ventavis) Endothelin-1 receptor antagonists Bosentan (Tracleer) Ambrisentan (Letairis) Sitaxsentan (Thelin) – available in Canada Sildenafil ...

Source : http://www.epcc.edu/ssin/Pharmacology_in_Nursing/Chapter_106.ppt

Sponsored Links
If you find powerpoint presentation a copyright It is important to understand and respect the copyright rules of the author.
Please do not download if you find presentation copyright.
If you find a presentation that is using one of your presentation without permission, contact us immidiately at

© XPowerPoint.com